Company Filing History:
Years Active: 2001-2013
Title: Innovations and Contributions of Peter Lobel
Introduction
Peter Lobel is a notable inventor based in Highland Park, NJ (US), recognized for his significant contributions to the field of medicine. He holds a total of 8 patents, showcasing his dedication to advancing medical science and therapeutic methods.
Latest Patents
Among his latest patents is the invention titled "Human lysosomal protein and methods of its use." This patent identifies and characterizes the gene associated with classical late infantile neuronal ceroid lipofuscinosis (LINCL), known as CLN2. The translation product of this gene is a novel protease, and a deficiency in this activity results in LINCL. The identification of CLN2 not only aids in the prevention of LINCL through genetic counseling but also provides strategies and test systems for therapeutic intervention. Furthermore, the characterization of this previously unknown lysosomal enzyme may offer valuable insights into other common human neurodegenerative disorders. Another significant patent is "Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein." This invention relates to a method for treating patients with disorders characterized by a deficient amount of functional CLN2 protein in affected cells. It involves administering an effective amount of CLN2 protein to reduce or eliminate symptoms caused by the deficiency.
Career Highlights
Peter Lobel has made remarkable strides in his career, particularly through his work at the University of Medicine and Dentistry of New Jersey. His research has focused on lysosomal disorders and neurodegenerative diseases, contributing to a better understanding of these complex conditions.
Collaborations
One of his notable collaborators is David Sleat, with whom he has worked on various research projects aimed at addressing lysosomal disorders.
Conclusion
Peter Lobel's innovative work and patents have significantly impacted the field of medicine, particularly in understanding and treating lysosomal disorders. His contributions continue to pave the way for future advancements in therapeutic interventions.